247 related articles for article (PubMed ID: 28696238)
1. Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing.
van Rijn SP; Srivastava S; Wessels MA; van Soolingen D; Alffenaar JC; Gumbo T
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696238
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.
van Rijn SP; Zuur MA; van Altena R; Akkerman OW; Proost JH; de Lange WC; Kerstjens HA; Touw DJ; van der Werf TS; Kosterink JG; Alffenaar JW
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137814
[TBL] [Abstract][Full Text] [Related]
3. Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.
Deshpande D; Pasipanodya JG; Srivastava S; Bendet P; Koeuth T; Bhavnani SM; Ambrose PG; Smythe W; McIlleron H; Thwaites G; Gumusboga M; Van Deun A; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S274-S283. PubMed ID: 30496459
[TBL] [Abstract][Full Text] [Related]
4. Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.
Davies Forsman L; Giske CG; Bruchfeld J; Schön T; Juréen P; Ängeby K
Int J Mycobacteriol; 2015 Mar; 4 Suppl 1():80-1. PubMed ID: 27128620
[TBL] [Abstract][Full Text] [Related]
5. Ertapenem and Faropenem against Mycobacterium tuberculosis: in vitro testing and comparison by macro and microdilution.
Gonzalo X; Satta G; Ortiz Canseco J; McHugh TD; Drobniewski F
BMC Microbiol; 2020 Aug; 20(1):271. PubMed ID: 32867678
[TBL] [Abstract][Full Text] [Related]
6. Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis.
Srivastava S; Modongo C; Siyambalapitiyage Dona CW; Pasipanodya JG; Deshpande D; Gumbo T
Antimicrob Agents Chemother; 2016 Oct; 60(10):5922-7. PubMed ID: 27458215
[TBL] [Abstract][Full Text] [Related]
7. d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.
Deshpande D; Alffenaar JC; Köser CU; Dheda K; Chapagain ML; Simbar N; Schön T; Sturkenboom MGG; McIlleron H; Lee PS; Koeuth T; Mpagama SG; Banu S; Foongladda S; Ogarkov O; Pholwat S; Houpt ER; Heysell SK; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S308-S316. PubMed ID: 30496460
[TBL] [Abstract][Full Text] [Related]
8. Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant
Singh S; Gumbo T; Boorgula GD; Thomas TA; Philley JV; Srivastava S
Antimicrob Agents Chemother; 2024 Feb; 68(2):e0108023. PubMed ID: 38131673
[TBL] [Abstract][Full Text] [Related]
9. Once-a-week tigecycline for the treatment of drug-resistant TB.
Deshpande D; Magombedze G; Srivastava S; Bendet P; Lee PS; Cirrincione KN; Martin KR; Dheda K; Gumbo T
J Antimicrob Chemother; 2019 Jun; 74(6):1607-1617. PubMed ID: 30820554
[TBL] [Abstract][Full Text] [Related]
10. Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis.
Srivastava S; Magombedze G; Koeuth T; Sherman C; Pasipanodya JG; Raj P; Wakeland E; Deshpande D; Gumbo T
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584143
[TBL] [Abstract][Full Text] [Related]
11. A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way.
Deshpande D; Srivastava S; Nuermberger E; Pasipanodya JG; Swaminathan S; Gumbo T
Clin Infect Dis; 2016 Nov; 63(suppl 3):S95-S101. PubMed ID: 27742640
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis.
van Rijn SP; van Altena R; Akkerman OW; van Soolingen D; van der Laan T; de Lange WC; Kosterink JG; van der Werf TS; Alffenaar JW
Eur Respir J; 2016 Apr; 47(4):1229-34. PubMed ID: 26743484
[TBL] [Abstract][Full Text] [Related]
13. Is there a place for β-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate.
Gonzalo X; Drobniewski F
J Antimicrob Chemother; 2013 Feb; 68(2):366-9. PubMed ID: 23070734
[TBL] [Abstract][Full Text] [Related]
14. Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.
Deshpande D; Pasipanodya JG; Mpagama SG; Bendet P; Srivastava S; Koeuth T; Lee PS; Bhavnani SM; Ambrose PG; Thwaites G; Heysell SK; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S293-S302. PubMed ID: 30496461
[TBL] [Abstract][Full Text] [Related]
15. Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis.
Deshpande D; Srivastava S; Bendet P; Martin KR; Cirrincione KN; Lee PS; Pasipanodya JG; Dheda K; Gumbo T
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29180526
[TBL] [Abstract][Full Text] [Related]
16. [
Shi J; Zheng DW; Ma XG; Su RY; Zhu YK; Wang SH; Chang WJ; Sun GQ; Sun DY
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Aug; 46(8):797-805. PubMed ID: 37536990
[No Abstract] [Full Text] [Related]
17. Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.
Pasipanodya JG; Nuermberger E; Romero K; Hanna D; Gumbo T
Clin Infect Dis; 2015 Aug; 61 Suppl 1():S10-7. PubMed ID: 26224767
[TBL] [Abstract][Full Text] [Related]
18. Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.
Srivastava S; Deshpande D; Pasipanodya J; Nuermberger E; Swaminathan S; Gumbo T
Clin Infect Dis; 2016 Nov; 63(suppl 3):S102-S109. PubMed ID: 27742641
[TBL] [Abstract][Full Text] [Related]
19. Ethambutol and meropenem/clavulanate synergy promotes enhanced extracellular and intracellular killing of
Olivença F; Pires D; Silveiro C; Gama B; Holtreman F; Anes E; Catalão MJ
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0158623. PubMed ID: 38411952
[TBL] [Abstract][Full Text] [Related]
20. In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Multidrug-Resistant Mycobacterium tuberculosis Isolates.
Zhang D; Wang Y; Lu J; Pang Y
Antimicrob Agents Chemother; 2016 Jan; 60(1):393-9. PubMed ID: 26525785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
